rs1718119 — P2RX7 Ala348Thr

Gain-of-function variant in the P2X7 receptor that increases ATP-gated pore formation, IL-1β release, and microglial neuroinflammation, associated with mood disorders and chronic pain severity

See your personal result for P2RX7

Upload your DNA data to find out which genotype you carry and what it means for you.

Upload your DNA data

Works with 23andMe, AncestryDNA, and other DNA test exports. Results in under 60 seconds.

P2RX7 Ala348Thr — A Gain-of-Function Variant That Amplifies Neuroinflammatory Signalling

The P2X7 receptor is an ATP-gated ion channel11 ATP-gated ion channel
The receptor opens in response to high concentrations of extracellular ATP, released during tissue damage, chronic stress, and cell death as a danger signal expressed predominantly on microglia — the brain's resident immune cells. When activated, P2X7 triggers the NLRP3 inflammasome, releases interleukin-1β (IL-1β), and drives neuroinflammation implicated in mood disorders, chronic pain, and neurodegeneration. The Ala348Thr variant (rs1718119) is the mirror image of the Glu496Ala loss-of-function variant22 mirror image of the Glu496Ala loss-of-function variant
rs3751143 reduces P2X7 activity by 70–90%; rs1718119 increases it beyond baseline in the same gene — where Glu496Ala silences the receptor, Ala348Thr turns it up. Carrying this common variant (the A allele is present in approximately 62% of people globally) amplifies the receptor's capacity for pore formation and inflammatory cytokine release, with documented effects on neuropathic pain, mood disorders, and inflammatory diseases such as gout.

The Mechanism

Residue 348 sits in the transmembrane domain 2 region33 transmembrane domain 2 region
The intramembrane and juxtamembrane domains of P2X7 control gating kinetics, pore dilation, and surface trafficking of the P2X7 receptor. The substitution of alanine (non-polar) for threonine (polar, hydroxyl-bearing) at this position alters receptor conformation in a way that increases total P2X7 protein expression at the cell surface and enhances downstream signalling. In functional studies using HEK-293 cells expressing the 348Thr mutant, pore function reached 218% of wild-type levels44 218% of wild-type levels
Measured as Yo-Pro-1 dye uptake, an established assay for large-pore formation capacity, while channel function (calcium flux) reached 137% of wild-type. The agonist sensitivity (EC50) remained similar to wild-type, meaning the receptor responds to normal ATP concentrations — it just responds more strongly and produces a larger pore for a given stimulus. In immune cells (THP-1 monocytic cells), the Ala348Thr receptor drives elevated IL-1β secretion55 drives elevated IL-1β secretion
IL-1β is the master proinflammatory cytokine released downstream of NLRP3 inflammasome activation and markedly upregulates NLRP3 expression when stimulated with ATP. In microglia specifically, this amplified P2X7→NLRP3→IL-1β axis is implicated in chronic neuroinflammation observed in depression, bipolar disorder, and neurodegeneration.

The Evidence

Pain. The most direct clinical data come from a 2014 study of patients with diabetic peripheral neuropathic pain66 2014 study of patients with diabetic peripheral neuropathic pain
n=156 Caucasian patients; genotype × sex interaction was a key finding. Female patients homozygous for the A allele (AA genotype) had a covariate-adjusted 1.7-point higher mean baseline pain score than GG homozygotes. Male patients showed no association (p=0.54), suggesting that sex hormones modulate how P2X7 gain-of-function translates into clinical pain — a pattern consistent with known sex differences in microglial activation.

Mood disorders. Multiple independent lines of evidence link rs1718119 to affective pathology. A 2022 bipolar disorder study77 2022 bipolar disorder study
Two sets: n=171 and n=475 bipolar patients on medication found that the A allele was significantly associated with a cluster of cognitive manic symptoms — distractibility, talkativeness, and thought disorder — with consistent odds ratios across two independent sample sets (OR 1.78, OR 1.42; combined OR 1.49, p<0.001). A 2019 study across MDD and diabetes cohorts88 2019 study across MDD and diabetes cohorts
n=315 inpatients with MDD or bipolar disorder + 406 controls + 218 diabetes patients found Ala348Thr associated with higher HADS depression severity scores in dimensional analyses, though categorical case-control comparisons showed only haplotype-level associations. A 2023 review supports the neuroinflammatory mechanism: chronic stress → elevated extracellular ATP → P2X7 activation → NLRP3 inflammasome assembly → IL-1β release in the hippocampus99 chronic stress → elevated extracellular ATP → P2X7 activation → NLRP3 inflammasome assembly → IL-1β release in the hippocampus, a pathway that rs1718119 gain-of-function would amplify.

Multiple sclerosis severity. A 2022 study of 128 RRMS patients1010 2022 study of 128 RRMS patients
Relapsing-remitting MS; MS severity score (MSSS) used as outcome found that A allele carriers had nearly double the MS severity score compared to GG homozygotes (mean MSSS 4.4 vs 2.3, p<0.001), with the association surviving adjustment for disease duration, age at onset, and HLA-DRB1 status (OR 1.2, 95% CI 1.0–1.4). The authors conclude Ala348Thr acts as a modulator of neuroinflammatory disease severity.

Gout. A 2023 functional and clinical study1111 2023 functional and clinical study
270 gout patients vs 70 hyperuricemic controls without gout attacks demonstrated that under high uric acid conditions, the Ala348Thr receptor shows markedly enhanced P2X7→NLRP3→IL-1β activation. The AA and AG genotypes conferred higher gout risk versus GG homozygotes, providing a direct mechanistic link between this gain-of-function variant and the IL-1β-driven inflammation of acute gouty arthritis.

Practical Implications

The Ala348Thr variant is common — the A allele is present in roughly 62% of the global population, meaning the AA or AG genotype is found in approximately 62% of people. This makes it a background factor rather than a rare high-impact variant. The gain-of-function amplifies inflammatory responses to danger signals, which in everyday terms means that under conditions of chronic stress, tissue damage, or metabolic insult, your immune cells may mount a stronger and more sustained inflammatory response. For people with the AA genotype, this creates a biologically grounded rationale for attentive management of neuroinflammatory risk factors: sleep, stress, diet, and omega-3 balance.

For women specifically, the pain sensitivity finding is notable: female AA carriers show higher chronic pain scores in neuropathic pain states. This doesn't predict pain in healthy individuals but suggests that if neuropathic or inflammatory pain develops, it may be more severe and merit earlier aggressive management.

The mood disorder connections are statistically robust but represent increased susceptibility, not predetermination. Approaches that reduce neuroinflammation — regular physical activity, omega-3 fatty acids (which antagonize the arachidonic acid pathway feeding NLRP3), adequate sleep, and stress management — have evidence-based rationale as risk modifiers for carriers.

Interactions

Rs1718119 is one of several functionally significant variants in the highly polymorphic P2RX7 gene. It has the opposite functional effect of rs3751143 (Glu496Ala): where Glu496Ala reduces P2X7 function by 70–90%, Ala348Thr increases it to 218% of wild-type pore capacity. An individual carrying both variants would have partially opposing effects, and the net phenotype depends on which alleles are inherited on the same chromosome. Rs208294 (His155Tyr) is a second gain-of-function variant in P2X7; its co-presence with rs1718119 was associated with pain in the diabetic neuropathy study. Rs7958311 (Arg270His) has unique dissociation of channel vs pore function and has been consistently linked to fibromyalgia and irritable bowel syndrome. Rs2230912 (Gln460Arg) has been the most studied in depression, with a meta-analysis confirming its association; it is in partial linkage disequilibrium with rs1718119 in European populations, meaning some of the observed mood associations may reflect shared haplotype effects rather than independent contributions of each SNP.

Genotype Interpretations

What each possible genotype means for this variant.

GG Baseline P2X7 Function Normal

Standard P2X7 receptor activity with normal ATP-induced inflammatory responses

You have two copies of the reference G allele, which encodes alanine at position 348. Your P2X7 receptors function at baseline capacity — responding to extracellular ATP danger signals with standard pore formation, calcium influx, and IL-1β release. Approximately 38% of people share this genotype. Your neuroinflammatory baseline is not amplified by this variant; your pain sensitivity and mood disorder risk are influenced by other factors, not by P2RX7 Ala348Thr.

AG Elevated P2X7 Activity Intermediate

One gain-of-function allele, moderately elevated P2X7 pore formation and inflammatory signalling

The heterozygous AG state produces a partial gain-of-function. Studies show the Ala348Thr variant acts in a codominant fashion, with functional effects scaling from GG < AG < AA. In immune cells, the Thr variant enhances NLRP3 inflammasome assembly and IL-1β release; one copy of the variant is sufficient to shift responses above baseline. In the context of mood disorders, the association signals for rs1718119 are broadly consistent with a codominant model. The practical significance for heterozygous carriers is that conditions associated with elevated extracellular ATP — chronic psychological stress, repeated tissue injury, metabolic dysfunction, and high uric acid states — may produce stronger inflammatory responses than in GG individuals. This creates a biologically meaningful rationale for managing modifiable neuroinflammatory risk factors proactively.

AA High P2X7 Activity High

Two gain-of-function alleles — significantly elevated P2X7 pore formation, IL-1β release, and neuroinflammatory tone

The homozygous gain-of-function state produces the strongest P2X7 amplification. Functional studies confirm pore formation at 218% and channel function at 137% of wild-type, driven by increased surface receptor expression. In immune and brain cells, this means that whenever ATP danger signals are released — during chronic stress, tissue damage, metabolic challenge, or infection — your cells mount a stronger and more sustained inflammatory cascade via the P2X7→NLRP3→IL-1β pathway.

The clinical consequences are multifaceted. For pain: in diabetic peripheral neuropathic pain, AA women had 1.7-point higher pain intensity scores than GG women after covariate adjustment — a clinically meaningful difference. For mood: the A allele at rs1718119 is one of several P2RX7 signals associated with both depressive symptom severity and cognitive manic features in bipolar disorder (OR 1.49 for cognitive manic symptom cluster, p<0.001). For inflammatory disease: in gout, AA/AG genotypes confer higher risk of acute attacks at any given uric acid level; in multiple sclerosis, A allele carriers had nearly double the severity scores of GG homozygotes.

The good news is that P2X7 signalling is modifiable through lifestyle and nutritional factors, and several pharmacological agents (omega-3-derived specialized pro-resolving mediators, cannabinoids, and investigational P2X7 antagonists) can attenuate this pathway. Sex is an important modifier: the pain associations were sex-specific (females only), while the mood associations appear to affect both sexes.